Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

CHEMBL96741 4-[3-(cyclopropylmethyl)-5- (4...

Synonyms: AG-J-92190, SureCN4915662, CTK7C0283, DNC007141, SB-216995, ...

Wilson, K.P. et al., Revesz, L. et al., Wang, Z. et al., Miyazawa, K. et al., Huang, M. et al., et al.

Stelmach, Liu, Patel, Pivnichny, Scapin, Singh, Hop, Wang, Strauss, Cameron, Nichols, O'Keefe, O'Neill, Schmatz, Schwartz, Thompson, Zaller, Doherty, Miyazawa, Mori, Miyata, Akahane, Ajisawa, Okudaira, Revesz, Di Padova, Buhl, Feifel, Gram, Hiestand, Manning, Wolf, Zimmerlin,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of SB6

Pyridinylimidazole compounds are specific inhibitors of p38 MAP kinase that block the production of the cytokines interleukin-1beta and tumor necrosis factor alpha, and they are effective in animal models of arthritis, bone resorption and endotoxin shock [1].

High impact information on SB6

A pyridinylimidazole compound, SB203580, completely inhibited the ability of p38 MAP kinase activity to phosphorylate PHAS-1 substrate [2].
A pyridinylimidazole compound, SB203580, inhibited p38 MAP kinase activity in vivo, since the activity of MAPKAP kinase-2 (a substrate of p38 MAP kinase) in IL-1beta-stimulated FLSs was totally suppressed by it [3].
The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase [1].
Specific inhibitors of Erk-1/2 (2'-amino-3'-methoxyflavone, PD98059) and P38 MAPK (pyridinylimidazole, SB203580) were found to suppress the uPA expression and the uPA promoter activity [4].
These analogues are hybrids of a pyridinylimidazole p38alpha inhibitor reported by Merck Research Laboratories and VX-745 [5].

Biological context of SB6

Mutagenesis showed that a single residue difference between p38 MAP kinase and other MAP kinases is sufficient to confer selectivity among pyridinylimidazole compounds [1].

Anatomical context of SB6

Recently we reported that the pyridinylimidazole class of p38 mitogen-activated protein (MAP) kinase inhibitors potently inhibited the facilitated transport of nucleosides and nucleoside analogs in K562 cells [6].

Associations of SB6 with other chemical compounds

The anti-inflammatory agent pyridinylimidazole and its analogs (SB [SmithKline Beecham] compounds) are highly potent and selective inhibitors of p38, but not of the closely-related ERK2, or other serine/threonine kinases [7].

Gene context of SB6

Pyridinylimidazole 11 potently inhibited LPS-induced TNFalpha in mice, showed good efficacy in the established rat adjuvant (ED(50): 10 mg/kg po b.i.d.) and collagen induced arthritis (ED(50): 5 mg/kg po b.i.d.) with disease modifying properties based on histological analysis of the joints [8].

References

The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Wilson, K.P., McCaffrey, P.G., Hsiao, K., Pazhanisamy, S., Galullo, V., Bemis, G.W., Fitzgibbon, M.J., Caron, P.R., Murcko, M.A., Su, M.S. Chem. Biol. (1997) [Pubmed]
Regulation of interleukin-1beta -induced platelet-derived growth factor receptor-alpha expression in rat pulmonary myofibroblasts by p38 mitogen-activated protein kinase. Wang, Y.Z., Zhang, P., Rice, A.B., Bonner, J.C. J. Biol. Chem. (2000) [Pubmed]
Regulation of interleukin-1beta-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by p38 mitogen-activated protein kinase. Miyazawa, K., Mori, A., Miyata, H., Akahane, M., Ajisawa, Y., Okudaira, H. J. Biol. Chem. (1998) [Pubmed]
Regulation of urokinase plasminogen activator by epigallocatechin-3-gallate in human fibrosarcoma cells. Kim, M.H., Jung, M.A., Hwang, Y.S., Jeong, M., Kim, S.M., Ahn, S.J., Shin, B.A., Ahn, B.W., Jung, Y.D. Eur. J. Pharmacol. (2004) [Pubmed]
Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase. Stelmach, J.E., Liu, L., Patel, S.B., Pivnichny, J.V., Scapin, G., Singh, S., Hop, C.E., Wang, Z., Strauss, J.R., Cameron, P.M., Nichols, E.A., O'Keefe, S.J., O'Neill, E.A., Schmatz, D.M., Schwartz, C.D., Thompson, C.M., Zaller, D.M., Doherty, J.B. Bioorg. Med. Chem. Lett. (2003) [Pubmed]
Inhibition of nucleoside transport by protein kinase inhibitors. Huang, M., Wang, Y., Cogut, S.B., Mitchell, B.S., Graves, L.M. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
Structural basis of inhibitor selectivity in MAP kinases. Wang, Z., Canagarajah, B.J., Boehm, J.C., Kassisà, S., Cobb, M.H., Young, P.R., Abdel-Meguid, S., Adams, J.L., Goldsmith, E.J. Structure (1998) [Pubmed]
SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors. Revesz, L., Di Padova, F.E., Buhl, T., Feifel, R., Gram, H., Hiestand, P., Manning, U., Wolf, R., Zimmerlin, A.G. Bioorg. Med. Chem. Lett. (2002) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.